Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Estrogen Exposure May Provide Protection from PSP

Mov Disord; ePub 2018 Feb 20; Park, Ilango, et al

A recent case-control study suggests a protective role of lifetime estrogen exposure in progressive supranuclear palsy (PSP). Researchers evaluated the self-reported reproductive characteristics and estrogen of 150 women with PSP and 150 age-matched female controls who participated in the Environmental Genetic-PSP study. Conditional logistic regression models were generated to examine associations of PSP with estrogen. They found:

  • There was no association between years of estrogen exposure duration and PSP.
  • There was a suggestion of an inverse association between composite estrogen score and PSP that did not reach statistical significance.
  • Any exposure to estrogen replacement therapy halved the risk of PSP.
  • Among PSP cases, earlier age at menarche was associated with better performance on Hoehn and Yahr stage and Unified Parkinson's Disease Rating Scale II score at clinical examination.
Citation:

Park HK, Ilango S, Charriez CM, et al. Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. [Published online ahead of print February 20, 2018]. Mov Disord. doi:10.1002/mds.27336.

Must Reads in Movement Disorders

Tourette, CTD, and Cardiometabolic Disorders Link, JAMA Neurology; ePub 2018 Jan 14; Brander, et al

Study Compares 2 Cognitive Assessment Tools, Mov Disord; ePub 2018 Dec 10; Hendershott, et al

White Matter Differences Between ET and PD, Neurology; ePub 2018 Nov 30; Juttukonda, et al

Physical Activity and Clinical Progression in PD, Parkinsonism Relat Disord; ePub 2018 Dec 10; Amara, et al

Analyzing the Spectrum of Visual Symptoms in PD , Front Neurol; ePub 2018 Nov 27; Barrell, et al